---
title: "Alnylam Pharmaceuticals slips in regular trading after intraday surge fades"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292227242.md"
description: "Alnylam (ALNY.US) slipped to $322.30 after intraday surge faded. Rose 12% yesterday on competitor drug trial failure."
datetime: "2026-07-09T17:14:26.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292227242.md)
  - [en](https://longbridge.com/en/news/292227242.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292227242.md)
generator: "portal-rs"
---

# Alnylam Pharmaceuticals slips in regular trading after intraday surge fades

阿里拉姆制药 (ALNY.US) 盘中微跌**0.37%**，现报**322.30**美元。

该股盘中触发 5 分钟急涨信号，但随后涨幅回落。消息面上，该公司昨日（07/09）曾因竞争对手 Ionis-AZ 心脏病药物三期试验未能达到主要终点而上涨**12%**。作为同类药物开发商，阿里拉姆制药受益于竞争格局变化。

### Related Stocks

- [ALNY.US](https://longbridge.com/en/quote/ALNY.US.md)

## Related News & Research

- [Alnylam (ALNY) Stock May Look Rich On Earnings Despite Weaker Price Action](https://longbridge.com/en/news/296831406.md)
- [16:00 ET(NASDAQ: ALNY) Investor Alert: Kessler Topaz Meltzer & Check, LLP Encourages Alnylam Pharmaceuticals, Inc. Investors to Contact the Firm](https://longbridge.com/en/news/296687484.md)
- [Alnylam Pharmaceuticals misses Q2 street views](https://longbridge.com/en/news/294375290.md)
- [16:58 ETInvestor Alert: Kessler Topaz Meltzer & Check, LLP Encourages Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) Investors to Contact the Firm](https://longbridge.com/en/news/296031373.md)
- [Alnylam’s $3.31 Billion Investment Portfolio Faces Rising Credit, Market and Interest Rate Risks](https://longbridge.com/en/news/294473931.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**